By Clinical Research Staff 

July 31, 2025 | TrialX has joined a partnership with the ALS Network; Fred Hutch Cancer Center has launched the Vanguard Study, a national study of a new type of blood test that screens several different cancers called multi-cancer detection (MCD) tests; and more. 

TrialX has joined a partnership with the ALS Network. TrialX’s global clinical trial finder was selected to power the ALS Network’s Trial Finder, an up-to-date resource to help the ALS community easily find information on latest clinical trials focusing on amyotrophic lateral sclerosis (ALS) and other similar motor neuron diseases. The tool guides users through personalized questions to generate trial matches based on their location and health history. It also offers advanced filters for independent searching by keyword, trial type, phase, and geography. Press release.

Velocity announced a strategic partnership with Palantir to automate and streamline the notoriously complex payments reconciliation process in clinical trials. Velocity and Palantir’s automated reconciliation solution integrates Palantir’s agentic AI technology with Velocity’s proprietary workflows. The application can process and reconcile customer payment report entries, which saves Velocity’s Finance Collections team a significant amount of time and frees them up to work on high-value tasks.  Press release.

Fred Hutch Cancer Center has launched the Vanguard Study, a national study of a new type of blood test that screens several different cancers called multi-cancer detection (MCD) tests. Researchers will evaluate whether these blood tests will help people ages 45 to 75 find cancer early when it may be easier to treat. The Vanguard Study is a pivotal first step in evaluating the feasibility of conducting large-scale randomized clinical trials to assess the effectiveness of MCD tests and other emerging cancer screening technologies. Its findings are intended to help shape the design and implementation of future studies aimed at advancing early cancer detection. Press release.

The Pistoia Alliance has launched two complementary initiatives to transform pharmacovigilance (PV) in response to growing member demand. A new dedicated AI in Safety & PV Community of Experts (CoE) will explore how to apply AI safely, ethically and effectively within pharmacovigilance workflows. While the Pharmacovigilance Systems & Processes Standards (PS²) project will establish a set of standard solution and integration requirements for PV systems to reduce duplicated effort and foster greater innovation in common PV workflows using AI. Press release. 

Evestia Clinical has merged with Atlantic Research Group (ARG) to create a leading independent global specialist contact research organization (CRO) group in fast-growing markets. The merger expands Evestia Clinical’s global footprint in the US and broadens its therapeutic services to include neurology and late-stage clinical trial services. The enlarged group also provides access to enhanced technologies to further meet the tailored needs of its clients. Press release.

GeniPhys has received 510(k) clearance from the FDA for its flagship product, Collymer Self-Assembling Scaffold (SAS). This milestone helps GeniPhys get one step closer to commercial launch, as well as introduces a novel solution in the wound care market. Collymer SAS is a two-part, flowable wound management device composed of a highly purified collagen solution and a self-assembly reagent. When combined, the solutions initiate in situ collagen self-assembly, forming a scaffold that supports cellular infiltration and vascularization. Press release.

Breakthrough Discoveries for thriving with Bipolar Disorder (BD²) and Brain Canada announced an international partnership to advance research and transform care for people living with bipolar disorder. As part of the partnership, BD² also announced its first international Integrated Network site at the Ottawa Hospital Research Institute. The BD² Integrated Network is the largest collaborative scientific network focused on bipolar disorder. As part of the partnership, the Ottawa Hospital Research Institute will receive $2.3 million to join the BD² Integrated Network, a collaborative research and clinical care model that will improve care, interventions, and outcomes for people living with bipolar disorder. Press release.

PhaseV has launched the ClinOps platform, a next-generation solution designed to modernize clinical trial operations through precision-guided site selection and dynamic performance monitoring. Built on causal machine learning and real-world patient-level data, the ClinOps platform enables study teams to move beyond historical benchmarks and make operational decisions with greater speed and accuracy. Press release.

Siemens AG completed the acquisition of Dotmatics. Dotmatics will form part of Siemens’ Digital Industries Software business to further expand Siemens’ Product Lifecycle Management (PLM) portfolio. The acquisition enables Siemens to scale its technologies into Life Sciences to fully address growth opportunities in this market. Dotmatics’ Scientific Intelligence Platform, Luma, and its scientific applications enable AI-powered multi-modal drug development, seamless collaboration, and contextualized data creating a connected digital thread across the research-to-production value chain. Press release.